Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Thompson

Showing results (611-620 of 637) with videos related to

Pageof 64
Sort By:
Frontiers in Psychiatry|January 22, 2019
The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice PerspectiveRenaud de Beaurepaire, Julia M A Sinclair, Mathis Heydtmann, et al.
The Lancet. Psychiatry|November 11, 2018
Baclofen for the treatment of alcohol use disorder: the Cagliari StatementRoberta Agabio, Julia Ma Sinclair, Giovanni Addolorato, et al.
Brain, Behavior, and Immunity|March 28, 2022
Machine learning based prediction and the influence of complement - Coagulation pathway proteins on clinical outcome: Results from the NEURAPRO trialSubash Raj Susai, David Mongan, Colm Healy, et al.
The Lancet. Infectious Diseases|October 4, 2014
A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidiumWilliam Checkley, A Clinton White, Devan Jaganath, et al.
Translational Psychiatry|October 28, 2022
Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosisSubash Raj Susai, Colm Healy, David Mongan, et al.
Early Intervention in Psychiatry|January 26, 2025
Exploring the Implementation of Cognitive Screening in First-Episode Psychosis Settings: The CogScreen Implementation StudyIsabel Zbukvic, Evangeline Fisher, Alexandra Stainton, et al.
Alcohol (Fayetteville, N.Y.)|December 27, 2017
Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosisJohn B Whitfield, Steven Masson, Suthat Liangpunsakul, et al.
Schizophrenia Bulletin|December 20, 2024
Characterizing the Clinical Trajectory and Predicting Persistence and Deterioration of Attenuated Psychotic Symptoms in Ultra-High-Risk IndividualsCassandra Wannan, Isabelle Scott, Dominic Dwyer, et al.
Hepatology (Baltimore, Md.)|August 28, 2020
Genome-wide Association Study and Meta-analysis on Alcohol-Associated Liver Cirrhosis Identifies Genetic Risk FactorsTae-Hwi Schwantes-An, Rebecca Darlay, Philippe Mathurin, et al.
JAMA Dermatology|March 25, 2026
Definition of Severity and Relapse for Vitiligo: An International Consensus StatementViktoria Eleftheriadou, Seemal Desai, Jung Min Bae, et al.
Pageof 64

Showing results (611-620 of 637) with videos related to

Sort By:
Pageof 64
Frontiers in Psychiatry|January 22, 2019
The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice PerspectiveRenaud de Beaurepaire, Julia M A Sinclair, Mathis Heydtmann, et al.
The Lancet. Psychiatry|November 11, 2018
Baclofen for the treatment of alcohol use disorder: the Cagliari StatementRoberta Agabio, Julia Ma Sinclair, Giovanni Addolorato, et al.
Brain, Behavior, and Immunity|March 28, 2022
Machine learning based prediction and the influence of complement - Coagulation pathway proteins on clinical outcome: Results from the NEURAPRO trialSubash Raj Susai, David Mongan, Colm Healy, et al.
The Lancet. Infectious Diseases|October 4, 2014
A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidiumWilliam Checkley, A Clinton White, Devan Jaganath, et al.
Translational Psychiatry|October 28, 2022
Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosisSubash Raj Susai, Colm Healy, David Mongan, et al.
Early Intervention in Psychiatry|January 26, 2025
Exploring the Implementation of Cognitive Screening in First-Episode Psychosis Settings: The CogScreen Implementation StudyIsabel Zbukvic, Evangeline Fisher, Alexandra Stainton, et al.
Alcohol (Fayetteville, N.Y.)|December 27, 2017
Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosisJohn B Whitfield, Steven Masson, Suthat Liangpunsakul, et al.
Schizophrenia Bulletin|December 20, 2024
Characterizing the Clinical Trajectory and Predicting Persistence and Deterioration of Attenuated Psychotic Symptoms in Ultra-High-Risk IndividualsCassandra Wannan, Isabelle Scott, Dominic Dwyer, et al.
Hepatology (Baltimore, Md.)|August 28, 2020
Genome-wide Association Study and Meta-analysis on Alcohol-Associated Liver Cirrhosis Identifies Genetic Risk FactorsTae-Hwi Schwantes-An, Rebecca Darlay, Philippe Mathurin, et al.
JAMA Dermatology|March 25, 2026
Definition of Severity and Relapse for Vitiligo: An International Consensus StatementViktoria Eleftheriadou, Seemal Desai, Jung Min Bae, et al.
Pageof 64